Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

Provided herein are polymers of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, compositions, and formulations thereof. The polymers described herein are biocompatible, non-toxic, water compatible, and operationally simple to formulate. Also provided are methods and kits involving the polymers described herein (e.g., methods of using polymers described herein for delivering agents (e.g., for therapeutic, diagnostic, prophylactic, imaging, ophthalmic, intraoperative, or cosmetic use) to a subject, cell, tissue, or biological sample, as part of materials (e.g., biodegradable materials, biocompatible materials, wound dressing (e.g., bandages), drug depots, coatings), or as scaffolds for tissue engineering. Provided are methods for synthesizing the polymers described herein, and polymers described herein synthesized by the synthetic methods described herein.

##STR00001##

A capped bisphenol polyether oligomer including a reactive end group, wherein the capped bisphenol polyether oligomer further includes a repeating unit derived from: a bisphenol monomer, a benzylic dihalide, a tertiary cycloalkyl dihalide, or a combination thereof; and optionally, the capped bisphenol polyether oligomer further includes a branching agent.

The present invention discloses a Y-type discrete polyethylene glycol derivative, which has the advantages of determined molecular weights and the number of chain segments, and can avoid the defect of heterogeneity of a PEG derivative. In addition, the Y-type discrete polyethylene glycol derivative of the present invention may increase the water solubility of the discrete polyethylene glycol, and solve the problem of insufficient water solubility of the discrete polyethylene glycol-modified insoluble drug caused by an increase of the loading capacity.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

A group of chiral conjugates (optically active hybrid molecules) of oligoetherpolyol structure are inhibitors of ATP-dependent reverse transporters of cells (OEP inhibitors). An OEP inhibitor is a conjugate having an equimolar ratio of optically active polyoxypropylene hexol and polyoxypropylene glycol. The produced preparation increases the efficacy of medicines by inhibiting multi-drug resistance mechanisms of cells. It may be used in biology, pharmacology, pharmaceutics, medicine, and agriculture. The inhibitor is produced by hydroxypropylation of a mixture of sorbitol and a bifunctional oxygen-containing compound in the presence of a hydroxide of an alkaline or alkaline earth metal. The bifunctional oxygen-containing compound used may be water, propylene glycol, dipropylene glycol, tripropylene glycol, tetrapropylene glycol, pentapropylene glycol, hexapropylene glycol, heptapropylene glycol or a mixture thereof. The inhibitor is a conjugate of polyoxypropylene glycol and polyoxypropylene hexol in an equimolar ratio, with a hydroxyl value within a range of 215-240 mg KOH/g.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

Described are a process for producing hydrosilylable polyoxyalkylene ethers, comprising the steps of (1) alkoxylation of at least one terminally unsaturated alcohol with alkylene oxides to afford a polyoxyalkylene ether, (2) etherification of the polyoxyalkylene ether from step (1) and (3) neutralization of the product from step (2) under buffered conditions, and hydrosilylable polyoxyalkylene ether mixtures.

The present invention provides an alkynyl multi-arm polyethylene glycol derivative having a structure of a general formula I or general formula X VIII. In the derivative, X1, X2, X3 and X4 are linking groups, F1, F2, F3 and F4 are end groups, the end groups may be the same or may also be different, and are selected from: hydroxy, carboxyl, ester group, amino, alkynyl or the like, at least one of the end groups is alkynyl, and PEG is the same or different (CH.sub.2CH.sub.2O).sub.m, wherein m is an integer ranging from 3 to 250, and l is an integer greater than or equal to 1. The multi-arm polyethylene glycol derivatives have stronger application flexibility, and have good application prospect in aspects such as organic synthesis, medicine synthesis and medical instruments. ##STR00001##